Tofacitinib 10 mg

DRUG6 trials

Conditions

Ankylosing SpondylitisCOVID-19 PneumoniaCovid19HealthyIleal PouchIleal PouchitisImmune-Mediated ColitisPouchitis

Phase 1

Tofacitinib Bioequivalence Study Comparing Tablets And Capsules

CompletedNCT01599377

PfizerHealthy

Start: 2012-05-31End: 2012-07-31Updated: 2012-07-10

Phase 2

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

CompletedNCT01786668

PfizerAnkylosing Spondylitis

Start: 2013-04-30End: 2015-03-31Updated: 2016-06-10

Tofacitinib for Treatment of Moderate COVID-19

TerminatedNCT04415151

Yale UniversityCOVID-19 Pneumonia

Start: 2020-10-14End: 2021-02-28Updated: 2025-03-28

Tofacitinib For Treatment Of Chronic Pouchitis

TerminatedNCT04580277

Cedars-Sinai Medical CenterIleal Pouch, Ileal Pouchitis, Pouchitis

Start: 2021-01-25End: 2023-05-15Updated: 2024-04-04

Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK Study

TerminatedNCT04768504

Khashayar EsfahaniImmune-Mediated Colitis

Start: 2022-03-22End: 2024-01-17Updated: 2024-11-25

Phase 3

Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

CompletedNCT04469114

Hospital Israelita Albert EinsteinCovid19

Start: 2020-09-16End: 2021-01-09Updated: 2021-08-09

2024-12-181 citations

Improvement of Fatigue in Patients with Ankylosing Spondylitis Receiving Tofacitinib: Analyses of a Phase 3 Randomized Controlled Trial.

2024-12-131 citations

Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials.

2024-12-053 citations

Laboratory profiles of patients hospitalized with COVID-19 pneumonia treated with tofacitinib or placebo: a post hoc analysis from the STOP-COVID trial.

2024-11-04

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status.

2024-09-252 citations

Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials

The Journal of Rheumatology2024-06-012 citations

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.

2024-05-025 citations

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis.

2023-06-234 citations

Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial.

2023-06-182 citations

Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis.

2022-09-2311 citations

Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial

RMD Open2022-06-0135 citations

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

New England Journal of Medicine2021-06-16437 citations

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.

2021-04-27169 citations

Can Tofacitinib Offer Protection against COVID-19 Infection?

Skin Appendage Disorders2021-01-011 citations

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.

2017-01-27249 citations

Tofacitinib 10 mg

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers